Bicycle Therapeutics Plc (BCYC)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Bicycle Therapeutics Plc (BCYC)
Go deeper and ask any question about BCYC
Company Performance
Current Price
as of Sep 17, 2024$24.41
P/E Ratio
N/A
Market Cap
$1.16B
Description
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Metrics
Overview
- HQCambridge, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBCYC
- Price$24.41-2.24%
Trading Information
- Market Cap$1.16B
- Float95.49%
- Average Daily Volume (1m)383,606
- Average Daily Volume (3m)278,044
- EPS-$3.81
Company
- Revenue$39.59M
- Rev Growth (1yr)-18.04%
- Net Income-$39.86M
- Gross Margin82.48%
- EBITDA Margin-559.95%
- EBITDA-$52.48M
- EV$133.69M
- EV/Revenue3.38
- P/EN/A
- P/S32.06
Documents
SEC Filings
Factset Street Account
Factset